Evidence map›Paper›PMID 40641030›Full record

ReviewCurrent drug targets2025

Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases.

Pranay Wal, Ankita Wal, Talha Jawaid, Paramita Ganguly, Binit Patel, Pankaj Nainwal, Mohd Qasid Lari, Ajay Kumar, Dileep Kumar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pranay WalPranveer Singh Institute of Technology, Pharmacy, NH-19, Bhauti Road, Kanpur UP, India.
Ankita WalPranveer Singh Institute of Technology, Pharmacy, NH-19, Bhauti Road, Kanpur UP, India.
Talha JawaidCollege of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Paramita GangulyDepartment of Pharmaceutical Technology, Brainware University Barasat West Bengal, India.
Binit PatelAnalyst in Quality Control at Hovione, 40 Lake Dr, East Windsor, NJ08520, United States.
Pankaj NainwalSchool of Pharmacy, Graphic Era Hill University, Dehradun, Uttarakhand, India.
Mohd Qasid LariSardar Patel College of Pharmacy, Medical College Road, Gorakhpur, India.
Ajay KumarSardar Patel College of Pharmacy, Medical College Road, Gorakhpur, India.
Dileep KumarDepartment of Pharm Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectiveHeterocyclic molecules, a mainstay of contemporary medicinal chemistry, are essential in developing antibacterial and anticancer treatments. Their distinct structural features-one or more heteroatoms within the ring-allow for a wide range of biological activities. With a focus on their modes of action and insights into the structure-activity relationship (SAR), this study examines the therapeutic uses of heterocyclic compounds in antibacterial, antifungal, antiviral, and anticancer treatments.

methodsThe review uses search engines like PubMed and Google Scholar, with a preference for English as the major language, to gather and analyse recent research on the antibacterial and anticancer applications of diverse heterocyclic compounds.

resultsIt has been discovered that heterocyclic chemicals are useful in blocking microbial enzymes, including DNA gyrase and the machinery involved in protein synthesis. Heterocyclic compounds such as benzimidazoles, quinolines, and acridines have demonstrated noteworthy efficacy in cancer therapy through their targeting of tubulin inhibition, DNA intercalation, and signalling pathways like PI3K/Akt/mTOR and MAPK. The pharmacological characteristics of these compounds were improved by the addition of electron-withdrawing groups, halogenation, and heteroatom replacements, according to SAR investigations.

conclusionHeterocyclic compounds have great promise for antibacterial and anticancer treatments. They are crucial in drug development because of their structural flexibility, which enables the targeted suppression of vital biological processes. The effectiveness of heterocyclic compounds will continue to be improved by ongoing advancements in drug design and SAR optimization, opening new possibilities for the creation of more potent and selective medicinal treatments.

Indexed as

Antineoplastic AgentsCommunicable DiseasesHeterocyclic CompoundsNeoplasmsAnimalsAnti-Bacterial AgentsAntiviral AgentsHumansStructure-Activity RelationshipAnti-Bacterial AgentsAntineoplastic AgentsAntiviral AgentsHeterocyclic Compoundsacridine derivativesantimicrobial therapybenzimidazole derivativescancer treatmentDNA intercalatorsHeterocyclic compoundstubulin inhibitors.

Identifiers

PMID40641030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.